PRINCETON, N.J., Aug. 15, 2012 /PRNewswire/ -- PeriGen, Inc., an innovative, national provider of fetal surveillance systems, today announced the publication of research on uterine tachysystole in the June issue of the Journal of Maternal-Fetal and Neonatal Medicine, which showed that high contraction rates were common in deliveries with normal blood gases at birth. The study revealed that fetal heart rate decelerations, in response to any level of contractions, and especially during the last two hours of labor, were more closely associated with metabolic acidosis than high contraction rates alone. Many babies were able to tolerate high contractions without consequence. More than 10% of the 3,636 patients in this study experienced contractions occurring more frequently than 5 in 10 minutes in times near delivery.
"This is the first large-scale study to measure how contraction rates evolve during labor, and the results of this study help to clarify the clinical significance of high contraction rates," said Emily Hamilton, MD, PeriGen's SVP of Clinical Research, and one of the authors of the study.
In addition to Dr. Hamilton, the authors of this study include Daniel O'Keeffe, MD, Executive Vice President of the Society for Maternal-Fetal Medicine, Thomas J. Garite, MD, Professor Emeritus at the University of California at Irvine School of Medicine, G. Eric Knox, MD, founding member of the National Patient Safety Foundation, and Philip Warrick, PhD, Senior Biomedical Research Engineer at PeriGen.
"Without PeriCALM Patterns, it would have been impossible to analyze the 13.7 miles of fetal heart rate tracings in this study," added Dr. Hamilton.
PeriCALM® Patterns™ is patented, electronic fetal monitoring pattern recognition software that identifies and measures baseline, baseline variability, fetal heart rate decelerations and uterine contractions during labor. The PeriCALM Patterns tool used to conduct this research is embedded in all of PeriGen's fetal monitoring and perinatal systems.
About PeriGen, Inc.
PeriGen is an innovative provider of fetal surveillance systems employing patented, pattern-recognition and obstetrics technologies that empower perinatal clinicians to make confident, real-time decisions about the mothers and babies in their care. PeriGen's customer-centric team of clinicians and technologists builds the most advanced systems available to augment obstetric decision-making and improve communications among the clinical team at the point of care, while supporting data flow between healthcare IT systems.
PeriGen's unique fetal surveillance products provide dynamic visual cues that direct clinicians to the most essential patient information displayed on the screen. Unlike legacy fetal monitoring devices and software from non-specialist companies, PeriGen Visual Cueing™ provides an instant view of the mother's and baby's current status and trends over time to avoid errors, increasing patient safety and reducing risk for clinicians and hospitals. For more information, please visit us at www.PeriGen.com.
Sandra Taylor, Ph.D.
Chief Marketing Officer, PeriGen
SOURCE PeriGen, Inc.